Background. Clinical trials indicate that the benefit of adding concurrent chemotherapy to radiotherapy of locally advanced @entity1149 ( @entity1149 ) for fit elderly is similar to the benefit for younger @entity1 . However, since elderly @entity1 are under-represented in most trials, the results might be due to selection bias, thus reports from a cohort of consecutively treated @entity1 are warranted. The current single institution study reports on the influence of age on survival of locally advanced @entity1149 @entity1 treated with radiotherapy combined with or without concurrent chemotherapy. Material and methods. Altogether, 478 @entity1 completed radical radiotherapy in doses of 60-66 Gy/30-33 fractions from 1995 to June 2012; 137 of the @entity1 had concurrent chemotherapy. The data was analyzed in age groups < 60, 60-69, and >=  70 years. Results. In the analyses of overall and @entity2 specific survival the hazard ratio was related to the use of concurrent chemotherapy was 0.49 (95% CI 0.29; 0.82), 0.68 (95% CI 0.48; 0.98) and 1.01 (95% CI 0.67; 1.51) for the age groups < 60, 60-69, and >=  70, respectively. Conclusion. Use of concurrent chemotherapy to radiotherapy of locally advanced @entity1149 was associated with a survival benefit in @entity1 younger than 70 years which was not the case for @entity1 older than 70 years, indicating the need to be careful when selecting elderly @entity1 for concurrent chemo-radiation.

Age dependent prognosis in concurrent chemo-radiation of locally advanced XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'non-small cell lung cancer'] @entity2 :: ('MESH:D008175', 'Disease') :: ['lung cancer']
@entity1149 :: (MESH:D002289,Disease) :: ['NSCLC']
